Financial Survey: iCAD (ICAD) & PAVmed (PAVM)

Share on StockTwits

PAVmed (NASDAQ:PAVM) and iCAD (NASDAQ:ICAD) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.

Insider and Institutional Ownership

1.9% of PAVmed shares are owned by institutional investors. Comparatively, 17.0% of iCAD shares are owned by institutional investors. 29.2% of PAVmed shares are owned by insiders. Comparatively, 10.1% of iCAD shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares PAVmed and iCAD’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
PAVmed N/A -9,092.93% -125.05%
iCAD -35.19% -65.03% -21.72%

Valuation and Earnings

This table compares PAVmed and iCAD’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
PAVmed N/A N/A -$17.97 million N/A N/A
iCAD $25.62 million 3.08 -$9.02 million ($0.38) -12.03

iCAD has higher revenue and earnings than PAVmed.

Risk & Volatility

PAVmed has a beta of 0.05, meaning that its stock price is 95% less volatile than the S&P 500. Comparatively, iCAD has a beta of 1.36, meaning that its stock price is 36% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for PAVmed and iCAD, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PAVmed 0 0 1 0 3.00
iCAD 0 0 0 0 N/A

PAVmed currently has a consensus target price of $3.00, indicating a potential upside of 156.41%. Given PAVmed’s higher possible upside, equities research analysts plainly believe PAVmed is more favorable than iCAD.

Summary

iCAD beats PAVmed on 6 of the 10 factors compared between the two stocks.

PAVmed Company Profile

PAVmed Inc. operates as a medical device company in the United States. The company's lead product pipeline includes CarpX, a percutaneous device to treat carpal tunnel syndrome; PortIO, an implantable intraosseous vascular access device; and DisappEAR, an antimicrobial resorbable ear tube. Its product pipeline also comprises NextCath, a self-anchoring catheter; NextFlo, a disposable infusion system; and Caldus, a disposable tissue ablation device. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was founded in 2014 and is based in New York, New York.

iCAD Company Profile

iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company provides electronic brachytherapy (eBX) products, including Axxent eBx systems for the treatment of early stage breast cancer, endometrial cancer, cervical cancer, and skin cancer, as well as for treating other cancers or conditions where radiation therapy is indicated comprising intraoperative radiation therapy. It also offers digital mammography computer-aided detection (CAD) products, such as advanced image analysis and workflow solutions in breast imaging, which include PowerLook Mammo Detection, which detects and identifies suspicious masses and micro-calcifications; and PowerLook Advanced Mammography Platform, a computer server residing on a customer's network that receives patient studies from the imaging modality, performs CAD and density assessment analysis, and sends the CAD results to picture archiving and communication system and/or review workstations. In addition, the company's digital mammography CAD products comprise magnetic resonance imaging products to detect breast and prostate cancer; breast tomosynthesis systems; and advanced image analysis and workflow solutions in computed tomography (CT) colonography, including VeraLook that supports the detection of colonic polyps in conjunction with CT colonography. It serves hospitals, ambulatory care centers and free standing radiation oncology facilities, and other office-based uses through sales organizations, as well as through various original equipment manufacturer partners, distributors, and resellers. iCAD, Inc. has a strategic partnership agreement with Invivo Corp. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was founded in 1984 and is headquartered in Nashua, New Hampshire.

Receive News & Ratings for PAVmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed and related companies with MarketBeat.com's FREE daily email newsletter.